Loading...
Market
Results of further CX-904 trials in pancreatic cancer by end of 2024
4
Resolution / Starting Odds
Significant tumor reduction in >75% of patients • 33%
Moderate tumor reduction in 50-75% of patients • 33%
Less than 50% of patients show tumor reduction • 34%
Clinical trial results published on clinicaltrials.gov or in peer-reviewed journals
Story
CytomX CX-904 Shows Promise in Pancreatic Cancer, Achieves $10M Milestones
May 8, 2024, 08:36 PM
CytomX Therapeutics announced positive initial Phase 1a dose escalation data for its monotherapy CX-904, an EGFRxCD3 PROBODY T-cell engager. The study reported measurable tumor reductions in eight patients, including two of six efficacy-evaluable pancreatic cancer patients who achieved confirmed partial responses per RECIST 1.1. All six pancreatic cancer patients reached disease control. Despite this, the results in other cancers like CRC, NSCLC, gastric, and HNSCC were less promising, with only partial responses observed in pancreatic cancer. The company's stock experienced significant volatility, surging 83% after hours following the announcement. CytomX has partnered with Amgen and achieved $10 million of milestones under a T-cell engaging bispecific collaboration with Astellas for preclinical progress on the first two programs. Further updates are expected by the end of 2024.
View original story
Similar markets
Prostate Cancer • 25%
Breast Cancer • 25%
Lung Cancer • 25%
Pancreatic Cancer • 25%
Colorectal Cancer • 25%
Pancreatic Cancer • 25%
Gastric Cancer • 25%
Ovarian Cancer • 25%
Below 50% effective • 25%
50%-70% effective • 25%
71%-90% effective • 25%
More than 90% effective • 25%
Additional Phase 3 trials • 33%
FDA Approval without additional trials • 33%
FDA Rejection • 33%
Pre-clinical • 25%
Phase 1 • 25%
Phase 2 • 25%
Phase 3 or beyond • 25%
Phase 4 trial initiated • 33%
Additional Phase 3 trial initiated • 33%
No further trials announced • 33%
Less than 25% • 25%
25-49% • 25%
50-74% • 25%
75% or more • 25%
Below 50% • 25%
50% to 75% • 25%
75% to 90% • 25%
Above 90% • 25%
New surgical techniques • 25%
Improved understanding of cancer history • 25%
No significant impact • 25%
Other • 25%
